Loading organizations...
§ Private Profile · Cambridge, MA, USA
An organization that operates in various sectors, with its primary business model and services currently undisclosed.
Cargene Therapeutics is a biopharmaceutical organization based in Singapore and Boston, Massachusetts, that focuses on the discovery and development of novel oligonucleotide therapeutics for cardiovascular and fibrotic diseases. The enterprise utilizes its proprietary technology platform to design highly specific small interfering RNA drugs aimed at addressing significant unmet medical needs across multiple therapeutic indications. To support the advancement of its preclinical pipeline and the expansion of its research capabilities, the company has raised $19 million in early-stage venture capital funding. This financial backing includes strategic investments from a syndicate of healthcare-focused venture capital firms, featuring recognizable entities such as BioTrack Capital, Hyfinity Investments, Legend Capital, and Trinity Innovation Fund. Operating with a specialized team of research scientists across its dual headquarters, Cargene Therapeutics was established in 2019 by co-founders Xiangang Zou and XQ Lin.
Cargene has raised $19.2M across 1 funding round.
Cargene has raised $19.2M in total across 1 funding round.
Cargene has raised $19.2M in total across 1 funding round.
Cargene's investors include Hyfinity Investments.
Cargene has raised $19.2M across 1 funding round. Most recently, it raised $19.2M Pre-Series A in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 15, 2021 | $19.2M Seed Plus | — | Hyfinity Investments | Announced |